Conventional and long-circulating liposomes of artemisinin: Preparation, characterization, and pharmacokinetic profile in mice

Journal of Liposome Research

Volumn 21, Issue 3, 2011, Pages 237-244

  Isacchi, Benedetta ^a   Arrigucci, Silvia ^a   Marca, Giancarlo La ^a,b   Bergonzi, Maria Camilla ^a   Vannucchi, Maria Giuliana ^a   Novelli, Andrea ^a   Bilia, Anna Rita ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Mass Spectrometry Clinical Chemistry and Pharmacology Lab   (Italy)

Author keywords

Artemisinin; Conventional liposomes; PEGylated liposomes; Pharmacokinetic properties in mice

Indexed keywords

ARTEMISININ; LIPOSOME; MACROGOL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTI-INFECTIVE AGENTS; ARTEMISININS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; LIPOSOMES; MALE; MICE; MOLECULAR STRUCTURE; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RANDOM ALLOCATION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 80051714511     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2010.539185     Document Type: Article

References (41)

1. Alberts, D. S., Liu, P. Y., Hanningan, E. V., et al. (1996). Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. NEJM 335:1950-1955.
2. Bangham, A. D., Standish, M. M., Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13:238-252.
3. Bayomi, M. A., Al-Angary, A. A., Al-Meshal, M. A., Al-Dardiri, M. M. (1998). In vivo evaluation of arteether liposomes. Int J Pharm 175:1-7.
4. Bilia, A. R., Melillo de Malghldhaes, P., Bergonzi, M. C., Vincieri, F. F. (2006). Simultaneous analysis of artemisinin and flavonoids of several extracts of Artemisia annua L. obtained from a commercial sample and a selected cultivar. Phytomedicine 13:487-493.
5. Bormann, S., Szlezak, N., Faucher, J. F., Matsiegui, P. B., Neubauer, R., Biner, R. K., et al. (2001). Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: A double-blind, randomized, placebo-controlled study. J Infect Dis 184:1363-1366.
6. Chen, Y., Xianfu, L., Hyunjin, P., Greever, R. (2009). Study of artemisinin nanocapsules as anticancer drug delivery systems. Nanomedicine 5:316-322.
7. Chimanuka, B., Gabriels, M., Detaevernier, M. R., Plaizier-Vercammen, J. A. (2002). Preparation of ß-artemether liposomes, their HPLC-UV evaluation, and relevance for clearing recrudescent parasitaemia in Plasmodium chabaudi malaria-infected mice. J Pharm Biomed Anal 28:13-22.
8. Duffy, P. E., Mutabingwa, T. K. (2004). Drug combinations for malaria: Time to ACT? Lancet 363:3-4.
9. Efferth, T., Dunstan, H., Sauerbrey, A., Miyachi, H., Chitambar, C. R. (2001). The anti-malarial, artesunate, is also active against cancer. Int J Oncol 18:767-773.
10. Gabriels, M., Plaizier-Vercammen J. (2003). Physical and chemical evaluation of liposomes, containing artesunate. J Pharm Biomed Anal 31:655-667.
11. Gibaldi, M., Perrier, D. (1982). Pharmacokinetics, 2nd ed. New York: Dekker.
12. Heppner, D. G., Ballou, V. R. (1998). Malaria in 1998: Advances in diagnosis, drugs, and vaccine development. Curr Opin Infect Dis 11:519-530.
13. Kirby, C., Gregoriadis, G. (1983). The effect of lipid composition of small unilamellar liposomes containing melphalan and vincristine on drug clearance after injection into mice. Biochem Pharmacol 32:609-615.
14. Klaiman, D. L. (1985). Quinghaosu (artemisinin): An antimalarial drug from China. Science 228:1049-1055.
15. Lai, H., Singh, N. P. (1995). Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett 91:41-46.
16. Lai, H., Singh, N. P. (2006). Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. Cancer Lett 231:43-48.
17. Lian, T., Ho, R. J. Y. (2001). Trends and developments in liposome drug delivery systems. J Pharm Sci 90:667-680.
18. Lin, Y. Y., Li, J. J., Chang, C. H., Lu, Y. C., Hwang, J. J., Tseng, Y. L., et al. (2009). Evaluation of pharamacokinetics of 111In-labeled VNBPEGylated liposomes after i.p. and i.v. administration in a tumor/ ascites mouse model. Cancer Biother Radiopharm 24:453-460.
19. Liu, D., Huang, L. (1992). Size homogeneity of a liposome preparation is crucial for liposome biodistribution in vivo. Liposomes Res 2:57-66.
20. Meshnick, S. R. (1998). Artemisinin antimalarials mechanism of action and resistance. Med Trop 58:13-17.
21. Meyer, H. W., Bunjes, H., Ulrich, A. S. (1999). Morphological transitions of brain sphingomyelin are determined by the hydration protocol: Ripples re-arrange in plane, and sponge-like networks distintegrate into small vesicles. Chem Phys Lipids 99:111-123.
22. Meyer, H. W., et al. (1998). Minimal radius of curvature of lipid bilayers in the gel phase state correspond to the dimension of biomembrane structures "caveolae." J Struct Biol 124:77-87.
23. Meyer, H. W., et al. (2000). Hydration of DMPC and DPPC at 4 degrees C produces a novel subgel phase with convex-concave bilayer curvatures. Chem Phys Lipids 105:149-166.
24. Meyer, H. W., Richter, W. (2001). Freeze-fracture studies on lipids and membranes. Micron 32:615-644.
25. Oussoren, C., Zuidema, J., Crommelin, D. J. A., Storm, G. (1997). Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition, and lipid dose. Biochim Biophys Acta 1328:261-272.
26. Parker, R. J., Hartman, K. D., Sieber, S. M. (1981a). Lymphatic absorption and tissue disposition of liposome-entrapped [14C] adriamycin following intraperitoneal administration to rats. Cancer Res 41:1311-1317.
27. Parker, R. J., Priester, E., Sieber, S. M. (1981b). Comparison of lymphatic uptake, metabolism, excretion, and biodistribution of free and liposome-entrapped [14C] cytosine b-D-arabinofuranoside following intraperitoneal administration to rats. Drug Metab Dispos 10:40-46.
28. Phillips, W. T., Andrews, T., Liu, H., Klipper, R., Landry, A. J., Jr., Blumhardt, R., et al. (2001). Evaluation of [99mTc] liposomes as lymphoscintigraphic agents: Comparison with [99mTc] sulfur colloid and [99mTc] human serum albumin. Nucl Med Biol 28:435-444.
29. Qinghaosu Antimalaria Coordinating Research Group. (1979). Antimalarial studies on qinghaosu. Chin Med J 92:811-816.
30. Romero, M. R., Efferth, T., Serrano, M. A., Castano, B., Macias, R. I., Briz, O., et al. (2005). Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an in vitro system. Antivir Res 68:75-83.
31. Sadzuka, Y., Hirota, S., Sonobe, T. (2000). Intraperitoneal administration of doxorubicin encapsulating liposomes against peritoneal dissemination. Toxicol Lett 116:51-56.
32. Sadzuka, Y., Nakai, S., Miyagishima, A., et al. (1997). Effects of administered route on tissue distribution and antitumor activity of PEG-coated liposomes containing adriamycin. Cancer Lett 111:77-86.
33. Singh, N. P., Lai, H. (2001). Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 70:49-56.
34. Singh, N. P., Lai, H. (2004). Artemisinin induces apoptosis in human cancer cells. Anticancer Res 24:2277-2280.
35. Titulaer, H. A. C., Zuidema, J., Lugt, C. B. (1991). Formulation and pharmacokinetics of artemisinin and its derivatives. Int J Pharm 69:83-92.
36. Ulrich, A. S., et al. (1999). Ultrastructural characterization of peptideinduce membrane fusion and peptide self-assembly in the lipid bilayer. Biophys J 77:829-841.
37. Utzinger, J., Xiao, S., N'Goran, E. K., Berquist, R., Tanner, M. (2001). The potential of artemether for the control of schistosomiasis. Int J Parasitol 31:1549-1562.
38. van Agtmael, M. A., Eggelte, T. A., van Boxtel, C. J. (1999). Artemisinin drugs in the treatment of malaria: From medicinal herb to registered medication. Trends Pharmacol Sci 20:199-205.
39. Wong, J. W., Yuen, K. H. (2003). Inclusion complexation of artemisinin with a-, ß-, and γ-cyclodextrins. Drug Dev Ind Pharm 29:1035-1044.
40. Wong, J. W., Yuen, K. H. (2001). Improved oral bioavailability of artemisinin through inclusion complexation with ß-and γ- cyclodextrins. Int J Pharm 227:177-185.
41. World Health Organization. (1994). The role of artemisinin and its derivatives in the current treatment of malaria (1994-1995). Report of an informal consultation convened by WHO in Gevena 27-29 September 1993 (p 94 mimeographed document WHO/ MAL/.1067). Geneva, Switzerland: World Health Organization.